Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies
NCT02118337Phase 2Completed
- Sponsor
- MedImmune
- Start
- May 2014
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of MEDI0680 in clear cell renal cell carcinoma (ccRCC) and malignant neoplasms (advanced stage) (9 arms), sponsored by MedImmune. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose-escalation Phase and Objective Response Rate (ORR) Based on Investigator-assessed Response Using RECIST v1.1 in Dose-expansion Phase. Started May 2014; status: completed.
02
Drugs
MEDI0680
03
Conditions
clear cell renal cell carcinoma (ccRCC)malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT02118337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118337.